Pfizer said that its cancer drug Ibrance did not meet the main goal in a late-stage trial testing the drug in patients with a specific type of early breast cancer, the latest setback in the company's attempt to expand the use of the drug.
According to the drugmaker, the collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative (HER2-) early breast cancer (eBC) who have residual invasive disease after completing neoadjuvant chemotherapy. The trial was sponsored by the German Breast Group (GBG) as part of a clinical research collaboration with Pfizer and other study groups.
"Despite this outcome, we believe that key learnings will emerge from the large number of biomarkers being analyzed from collected tumor tissue, which will help inform future breast cancer research,” said Professor Sibylle Loibl, Chair of GBG.
Ibrance is already approved in the U.S. to treat certain adult patients with advanced breast cancer which has spread to other parts of the body.
In June, Eli Lilly's rival drug, Verzenio, met the trial goal of reducing the risk of early-stage breast cancer from recurring.
Read the press release
